Specifically, the exclusion of CD8+ T cells from the tumor parenchyma correlated with signature of TGF-β signaling activation in fibroblasts in metastatic urothelial cancer patients, who were treated with an anti-PD-L1 agent (atezolizumab) [111]. Here, CD8A is linked to neoplasm.